Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
About this chapter Cite this chapter Rajalakshmi, R
According to Tsang, the most common oral GLP-1 side effects include: Dry mouth (xerostomia) Enamel erosion Dental cavities Tooth sensitivity Gingival inflammation Taste disturbances (dysguesia) The most common side effectdry mouthis likely caused by a few things, Tsang says
How Retatrutide Compares to Existing Therapies The progression from single to dual to triple agonist therapy represents a clear trend in obesity pharmacotherapy: Semaglutide (GLP-1 agonist): ~1517% weight loss in Phase III (STEP trials) Tirzepatide (GIP + GLP-1 dual agonist): ~2022.5% weight loss in Phase III (SURMOUNT trials) Retatrutide (GIP + GLP-1 + glucagon triple agonist): ~2629% weight loss in Phase III (TRIUMPH-4) Each additional receptor pathway appears to contribute incremental efficacy
The Nordic countries as a cohort for pharmacoepidemiological research
Encourage patients to choose a time and day of the week that will work, and encourage them to set a calendar reminder alert
